Compare Gilead Sciences, Inc. (GILD) vs ServiceNow Inc (NOW) Price & Performance

Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.

Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.

ServiceNow (NOW) trades at $104.85, down 5.76% over the past day, with a neutral technical signal. The stock shows strong fundamentals, with revenue growing from $7.2B in 2022 to $13.3B in 2025 and a robust gross profit margin of 76.56%. Recent earnings have mostly beaten expectations, and the company maintains positive operating cash flow. Analyst sentiment is overwhelmingly bullish, with an 85.51% buy rating and a consensus price target of $137.52, suggesting significant upside potential from current levels.

The outlook for NOW is positive, driven by its leadership in enterprise AI solutions and consistent financial performance. Investment opportunities include exposure to high-growth AI markets and strong cash generation. Key risks involve elevated valuation multiples, competitive pressures in the SaaS sector, and execution challenges in sustaining growth. The stock presents a compelling case for growth-oriented investors, though its high P/E ratio warrants caution amid market volatility.